George Magrath Purchases 100,000 Shares of Opus Genetics, Inc. (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) CEO George Magrath acquired 100,000 shares of Opus Genetics stock in a transaction on Thursday, December 26th. The stock was purchased at an average price of $0.98 per share, with a total value of $98,000.00. Following the purchase, the chief executive officer now owns 599,150 shares of the company’s stock, valued at $587,167. The trade was a 20.03 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

George Magrath also recently made the following trade(s):

• On Monday, November 18th, George Magrath bought 9,706 shares of Opus Genetics stock. The stock was acquired at an average cost of $1.02 per share, for a total transaction of $9,900.12.
• On Friday, November 15th, George Magrath acquired 90,294 shares of Opus Genetics stock. The shares were acquired at an average cost of $1.01 per share, for a total transaction of $91,196.94.

Opus Genetics Trading Up 6.2 %

Shares of IRD stock opened at $1.19 on Thursday. The company has a market capitalization of $37.57 million, a price-to-earnings ratio of -1.09 and a beta of 0.19. Opus Genetics, Inc. has a twelve month low of $0.81 and a twelve month high of $3.40.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The company had revenue of $3.87 million for the quarter, compared to analysts’ expectations of $1.17 million. On average, equities analysts expect that Opus Genetics, Inc. will post -1.22 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Opus Genetics in a research note on Thursday, December 12th.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.